A special section on the pharmacokinetic and drug metabolism properties of novel therapeutic modalities is being planned for publication in the October 2019 issue of Drug Metabolism and Disposition.  

The submission deadline is April 1, 2019.  

Original research pertaining to the pharmacokinetic, pharmacodynamic, metabolic, and/or distribution properties of emerging therapeutic modalities, including (but not limited to) fusion proteins, bispecific antibodies, oligonucleotides, proteolysis targeting chimeras, CAR-T cells, and viral or gene-based therapies will define the core area of interest for this special section. Manuscripts describing efforts to apply novel in vitro, bioanalytical, or modeling approaches to characterizing the ADME properties of these novel therapeutic modalities are highly encouraged.  Research papers pertaining to the ADME properties of peptides and peptidomimetics, antibody-drug conjugates, or nanoparticle therapeutics may also be considered. 

Review articles addressing any aspects of the pharmacokinetic, metabolic, or distribution properties of the aforementioned therapeutic modalities will be considered as well; proposals for such articles should be sent to the guest editors, Rob Foti (rfoti@amgen.com) or Brooke Rock (brooke@amgen.com), for approval prior to submission.